Ayako Kawabata
Overview
Explore the profile of Ayako Kawabata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morikawa K, Baba A, Matsushima S, Ohki Y, Shiraishi M, Kawabata A, et al.
Abdom Radiol (NY)
. 2024 Dec;
PMID: 39729099
Objectives: To comprehensively summarize the characteristics of magnetic resonance imaging (MRI) findings of uterine adenosarcoma through a systematic review and case series analysis. Methods: A literature search was conducted in...
2.
Matsuno K, Ueda K, Saito M, Kamii M, Tsuda A, Kawabata A, et al.
J Obstet Gynaecol Res
. 2024 Nov;
51(1):e16141.
PMID: 39530312
Aim: To investigate the effects of surgical menopause on bone mineral density and bone quality because bilateral salpingo-oophorectomy for the treatment of gynecological malignancies is common even in premenopausal patients....
3.
Iida Y, Yanaihara N, Yoshino Y, Saito M, Saito R, Tabata J, et al.
Front Oncol
. 2024 Feb;
14:1302850.
PMID: 38420012
PARP inhibitors have changed the management of advanced high-grade epithelial ovarian cancer (EOC), especially homologous recombinant (HR)-deficient advanced high-grade EOC. However, the effect of PARP inhibitors on HR-proficient (HRP) EOC...
4.
Hanai A, Kawabata A, Nakajima K, Masuda K, Urakawa I, Abe M, et al.
Front Physiol
. 2023 Feb;
14:1102751.
PMID: 36776964
Fibroblast growth factor 23 (FGF23), a hormone, mainly produced by osteocytes, regulates phosphate and vitamin D metabolism. By contrast, 1,25-dihydroxyvitamin D, the active form of vitamin D, has been shown...
5.
Morii E, Hatanaka Y, Motoi N, Kawahara A, Hamakawa S, Kuwata T, et al.
Pathobiology
. 2023 Feb;
90(5):289-311.
PMID: 36754025
Rapid advances are being made in cancer drug therapy. Since molecularly targeted therapy has been introduced, personalized medicine is being practiced, pathological tissue from malignant tumors obtained during routine practice...
6.
Ito K, Nakagawa M, Shimokawa M, Hori K, Tashima L, Goto M, et al.
Anticancer Drugs
. 2023 Feb;
34(7):857-865.
PMID: 36729915
Patients with advanced ovarian clear cell carcinoma (CCC) have a poor prognosis in the absence of an effective standard treatment. Combination therapy with gemcitabine, cisplatin, and bevacizumab (GPBev) is promising...
7.
Kawabata A, Hayashi T, Akasu-Nagayoshi Y, Yamada A, Shimizu N, Yokota N, et al.
Curr Issues Mol Biol
. 2022 Jun;
44(4):1587-1596.
PMID: 35723366
Epithelial ovarian cancer is classified into four major histological subtypes: serous, clear cell, endometrioid and mucinous. Ovarian clear cell carcinoma (OCCC) responds poorly to conventional chemotherapies and shows poor prognosis....
8.
Akasu-Nagayoshi Y, Hayashi T, Kawabata A, Shimizu N, Yamada A, Yokota N, et al.
Cancer Sci
. 2022 Apr;
113(6):2034-2043.
PMID: 35377528
Ovarian cancer is the fifth most common cause of cancer-related death in women. Ovarian clear cell carcinoma (OCCC) is a chemotherapy-resistant epithelial ovarian cancer with poor prognosis. As a basis...
9.
Onoda N, Kawabata A, Hasegawa K, Sakakura M, Urakawa I, Seki M, et al.
DNA Res
. 2022 Mar;
29(2).
PMID: 35325072
The kidney is a complex organ that consists of various types of cells. It is occasionally difficult to resolve molecular alterations and possible perturbations that the kidney experiences due to...
10.
Morikawa A, Kawabata A, Shirahige K, Akiyama T, Okamoto A, Sutani T
Gene
. 2021 Dec;
811:146083.
PMID: 34856363
Nearly three hundred thousand female patients are diagnosed with ovarian cancer in the world annually, and this number shows an increasing trend. However, characteristic symptoms caused by ovarian cancer are...